Presentation is loading. Please wait.

Presentation is loading. Please wait.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Published byRebecca Melissa Christiaens Modified over 5 years ago

Similar presentations

Presentation on theme: "Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous."— Presentation transcript:

1 Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous (s.c.) injection of NPH, detemir, and glargine insulin in type 2 diabetic subjects. Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous (s.c.) injection of NPH, detemir, and glargine insulin in type 2 diabetic subjects. Paola Lucidi et al. Dia Care 2011;34: ©2011 by American Diabetes Association

Download ppt "Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous."

Similar presentations

Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.

Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Mechanisms of diabetic neuropathy.

Mechanisms of diabetic neuropathy.
Figure 4 Amino acid structure of short-acting and long-acting insulins

Figure 4 Amino acid structure of short-acting and long-acting insulins
Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).
Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.
The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.
Figure 3 Pharmacodynamic action profiles of long-acting insulins

Figure 3 Pharmacodynamic action profiles of long-acting insulins
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Evolution of Insulin: From Human to Analog

Evolution of Insulin: From Human to Analog
One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.

Top panel: AUC0–31h of M1 and glargine in the nine individual subjects (M1, open circles; glargine, filled circles) and median and 10th, 25th, 75th, and.
Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.
1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.
Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.
TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Similar presentations

Ads by Google